Frontiers in Immunology (Sep 2023)

Lung inflammation and interstitial fibrosis by targeted alveolar epithelial type I cell death

  • Sandra Carignon,
  • Dorian De Moura Rodrigues,
  • David Gosset,
  • Elodie Culerier,
  • Sarah Huot-Marchand,
  • Florence Savigny,
  • Eric Kaya,
  • Valerie Quesniaux,
  • Aurélie Gombault,
  • Isabelle Couillin,
  • Bernhard Ryffel,
  • Marc Le Bert,
  • Nicolas Riteau

DOI
https://doi.org/10.3389/fimmu.2023.1261483
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionThe pathogenesis of chronic lung diseases is multifaceted with a major role of recurrent micro-injuries of the epithelium. While several reports clearly indicated a prominent role for surfactant-producing alveolar epithelial type 2 (AT2) cells, the contribution of gas exchange-permissive alveolar epithelial type 1 (AT1) cells has not been addressed yet. Here, we investigated whether repeated injury of AT1 cells leads to inflammation and interstitial fibrosis.MethodsWe chose an inducible model of AT1 cell depletion following local diphtheria toxin (DT) administration using an iDTR flox/flox (idTRfl/fl) X Aquaporin 5CRE (Aqp5CRE) transgenic mouse strain.ResultsWe investigated repeated doses and intervals of DT to induce cell death of AT1 cells causing inflammation and interstitial fibrosis. We found that repeated DT administrations at 1ng in iDTRfl/fl X Aqp5CRE mice cause AT1 cell death leading to inflammation, increased tissue repair markers and interstitial pulmonary fibrosis.DiscussionTogether, we demonstrate that depletion of AT1 cells using repeated injury represents a novel approach to investigate chronic lung inflammatory diseases and to identify new therapeutic targets.

Keywords